Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated for the MyRisk Hereditary Cancer Test, ensuring a seamless experience.

Since joining Myriad in December 2023, Sam has played an integral role in shaping the Company’s long-term growth strategy, while delivering new perspectives and expertise to advance our business initiatives,

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions,

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $42.5 million in its fourth quarter. On a per-share basis, the Salt Lake City-based company ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...